A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science namely human genome sequencing and rising sensitivity of detecting techniques and assays.
The global Liquid Biopsy market is currently valued at $3950 million and will reach $17,372.28 million growing at a CAGR of 28%. The growth factors responsible for this explosive growth are liquid biopsy is a comparatively painless and non-invasive technique which provides early real time high precision detection of diseases which could be used for monitoring and designing effective treatment strategies based on the real time molecular assessment for the progression of the disease. Other factors driving the liquid biopsy market are lifestyle changes and environmental factors such as rising investment in research and development and collaborations between companies and public organizations, rise in population particularly geriatric population, rising expenditure on health etc. The technique also has other advantages over traditional tissue biopsy such as potential applications to cardiovascular diseases, autoimmune diseases etc.
The restraints include the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. Also not all cancer patients benefit from early detection as some cancers such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Key Players for Global Liquid Biopsy market:
• Guardant Health, Inc.,
• Trovagene, Inc.,
• RainDance Technologies, Inc.,
• Agena Bioscience Inc. Inc.,
• Admera Health,
• Biocept, Inc.,
• Circulogene Theranostics,
• Inivata Ltd.,
• SAGA Diagnostics AB,
• Exosome Diagnostics
Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/710
Global Liquid Biopsy market has been segmented
On the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker.
On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application.
On the basis of sample; market is segmented into blood, urine and others.
On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.
Taste the market data and market information presented through more than 50 market data tables and figures spread in 110 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Liquid Biopsy Market Research Report- Forecast to 2022”
• Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
• On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
• The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period
Browse full report @ https://www.marketresearchfuture.com/reports/liquid-biopsy-market
Table of Content
1 Report Prologue
2.1 Scope Of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.2.1 Comparatively Painless And Non-Invasive Technique
4.2.2 Early Real Time High Precision Detection Of Diseases
4.2.3 Useful For Designing Effective Treatment Strategies Based On The Real Time Molecular Assessment For The Progression Of The Disease
4.2.4 Rise In Cases Of Cancer And Other Diseases
4.2.5 Lifestyle Changes And Environmental Factors
4.2.6 Other Advantages Over Other Techniques
4.2.7 The Recent Technological Advancements Has Increased The Appeal Of Liquid Biopsy
4.2.8 Transferability Of Liquid Biopsy
4.2.9 Rising Investment In Research And Development And Collaborations Between Companies And Public Organizations
4.2.10 Greater Focus On Venture Capital
4.2.11 Demographical Factors
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Chromatography systems Market information, by type (gas chromatography, liquid chromatography, and others), by end users (pharmaceutical and biotechnology industry, hospital and research laboratories, agriculture and food industry, and others) – Forecast to 2022.know more about this report @ https://www.marketresearchfuture.com/reports/chromatography-systems-market-2324
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312